The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Tumor cell expression of programmed cell death‐1 ligand 1 is a prognostic factor for malignant melanoma
Open accessAbstract
BACKGROUND: Melanoma tends to be refractory to various immunotherapies because of tumor‐induced immunosuppression. To investigate the mechanism underlining the immunosuppression of melanoma patients, the authors focused on programmed cell death‐1 (PD‐1)/PD‐1 ligand 1 (PD‐L1) interaction between tumor cells and T cells. METHODS: Melanoma specimens were collected from 59 primary tumors, 16 lymph nodes, and 4 lesions of in‐transit metastasis. Specimens stained with anti‐PD‐L1 monoclonal antibodies were digitalized to jpg files. To evaluate the intensity of PD‐L1 expression, histograms were used, and the red density (RD) was measured. PD‐1 expression on T cells was analyzed in blood samples from 10 patients who had stage IV melanoma and in 4 samples of in‐transit metastases. RESULTS: Twenty‐five patients comprised the “low” PD‐L1 expression group (RD value, <90), and 34 patients comprised the “high” group (RD value, ≥90). Breslow tumor thickness in the high‐expression group was significantly higher than in the low‐expression group. Univariate and multivariate analyses revealed that the overall survival rate of the high‐expression group was significantly lower than that of the low‐expression group. In all patients with stage IV disease who were examined, both CD8‐positive and CD4‐positive T cells had significantly higher PD‐1 expression levels in the peripheral blood. Tumor‐infiltrating T cells expressed high levels of PD‐1, and its expression was elevated further during the clinical course. CONCLUSIONS: The current results indicated that there is a correlation between the degree of PD‐L1 expression and the vertical growth of primary tumors in melanoma. Multivariate analysis demonstrated that PD‐L1 expression is an independent prognostic factor for melanoma. Cancer 2010. © 2010 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
Self-citationFinal Version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma
Balch, C. M., Buzaid, A. C., Soong, S.-J., Atkins, M. B., Cascinelli, N., Coit, D. G., Fleming, I. D., Gershenwald, J. E., Houghton, A., Kirkwood, J. M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.16.3635 · Cited by 2,636
Greenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Self-citationTissue expression of PD-L1 mediates peripheral T cell tolerance
Keir, M. E., Liang, S. C., Guleria, I., Latchman, Y. E., Qipo, A., Albacker, L. A., Koulmanda, M., Freeman, G. J., Sayegh, M. H., & Sharpe, A. H. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051776 · Cited by 1,211
Clemente, C. G., Mihm, M. C., Bufalino, R., Zurrida, S., Collini, P., & Cascinelli, N. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960401)77:7<1303::aid-cncr12>3.0.co;2-5 · Cited by 1,171
Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2746 · Cited by 889
B7-Dc, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells
Tseng, S.-Y., Otsuji, M., Gorski, K., Huang, X., Slansky, J. E., Pai, S. I., Shalabi, A., Shin, T., Pardoll, D. M., & Tsuchiya, H. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.7.839 · Cited by 872
Ohigashi, Y., Sho, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N., Mizuno, T., Yoriki, R., Kashizuka, H., Yane, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1469 · Cited by 796
The PD-1–PD-L pathway in immunological tolerance
Okazaki, T., & Honjo, T. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.02.001 · Cited by 721
Self-citationViguier, M., Lemaître, F., Verola, O., Cho, M.-S., Gorochov, G., Dubertret, L., Bachelez, H., Kourilsky, P., & Ferradini, L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.1444 · Cited by 686
Ghebeh, H., Mohammed, S., Al-Omair, A., Qattant, A., Lehe, C., Al-Qudaihi, G., Elkum, N., Alshabanah, M., Bin Amer, S., Tulbah, A., et al. (2006) · Neoplasia · doi:10.1593/neo.05733 · Cited by 612
Iwai, Y. (2004) · International Immunology · doi:10.1093/intimm/dxh194 · Cited by 527
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.
Strome, S. E., Dong, H., Tamura, H., Voss, S. G., Flies, D. B., Tamada, K., Salomão, D. R., Cheville, J. C., Hirano, F., Lin, W. Y., et al. (2003) · PubMed · Cited by 489
Inman, B. A., Sebo, T. J., Frigola, X., Dong, H., Bergstralh, E. J., Frank, I., Fradet, Y., Lacombe, L., & Kwon, E. D. (2007) · Cancer · doi:10.1002/cncr.22588 · Cited by 438
Wang, L., Pino-Lagos, K., de Vries, V. C., Guleria, I., Sayegh, M. H., & Noelle, R. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710441105 · Cited by 389
Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma
Enk, A. H., Jonuleit, H., Saloga, J., & Knop, J. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19971104)73:3<309::aid-ijc1>3.0.co;2-3 · Cited by 386
Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses in vitro
Blank, C., Kuball, J., Voelkl, S., Wiendl, H., Becker, B., Walter, B., Majdic, O., Gajewski, T. F., Theobald, M., Andreesen, R., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21775 · Cited by 297
Chen, Q., Daniel, V., Maher, D. W., & Hersey, P. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910560524 · Cited by 234
Wong, R. M., Scotland, R. R., Lau, R. L., Wang, C., Korman, A. J., Kast, W. M., & Weber, J. S. (2007) · International Immunology · doi:10.1093/intimm/dxm091 · Cited by 231
Strauss, L., Bergmann, C., Szczepanski, M. J., Lang, S., Kirkwood, J. M., & Whiteside, T. L. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.2967 · Cited by 165
Yang, W., Chen, P. W., Li, H., ALIZADEH, H. M., & Niederkorn, J. Y. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-1606 · Cited by 137
Nemunaitis, J. J., Fong, T. C., Shabe, P., Martineau, D., & Ando, D. G. (2001) · Cancer Investigation · doi:10.1081/cnv-100102550 · Cited by 131
He, Y., Zhang, G., Wang, X., Zhang, H., Yuan, Y., Li, D., & Feng, Z. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.4919 · Cited by 126
Mourmouras, V., BIAGIOLI, M., Miracco, C., Luzi, P., Tosi, P., Cosci, E., Monciatti, I., Mannucci, S., & Rubegni, P. (2007) · Oncology Reports · doi:10.3892/or.18.5.1115 · Cited by 100
Shimauchi, T., Kabashima, K., Nakashima, D., Sugita, K., Yamada, Y., Hino, R., & TOKURA, Y. (2007) · International Journal of Cancer · doi:10.1002/ijc.23042 · Cited by 94
Self-citationImmunosuppressive Dendritic and Regulatory T Cells are Upregulated in Melanoma Patients
McCarter, M. D., Baumgartner, J. M., Escobar, G. A., Richter, D., Lewis, K. D., Robinson, W. A., Wilson, C. C., Palmer, B. E., & Gonzalez, R. C. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9488-3 · Cited by 75
Benlalam, H., Labarrière, N., Linard, B., Derré, L., Diez, E., Pandolfino, M., Bonneville, M., & Jotereau, F. (2001) · European Journal of Immunology · Cited by 72
Melanoma Induces Immunosuppression by Up-Regulating FOXP3+ Regulatory T Cells
Baumgartner, J. M., Wilson, C. C., Palmer, B. E., Richter, D. A., Banerjee, A. M., & McCarter, M. D. (2007) · Journal of Surgical Research · doi:10.1016/j.jss.2007.03.053 · Cited by 71
Mourmouras, V., Fimiani, M., Rubegni, P., Epistolato, M. C., Malagnino, V., Cardone, C., Cosci, E., Nisi, M. C. D., & Miracco, C. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08057.x · Cited by 66
Immunity to Melanoma Antigens: From Self‐Tolerance to Immunotherapy
Slingluff, C. L., Chianese‐Bullock, K. A., Bullock, T. N. J., Grosh, W. W., Mullins, D. W., Nichols, L. A., Olson, W. C., Petroni, G. R., Smolkin, M. E., & Engelhard, V. H. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90007-8 · Cited by 65
Significance of B7-H1 Overexpression in Kidney Cancer
Thompson, R. H., & Kwon, E. D. (2006) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2006.n.038 · Cited by 45
Monocyte-derived IL-10 Expression Predicts Prognosis of Stage IV Melanoma Patients
Torisu‐Itakura, H., Lee, J. H., Huynh, Y., Ye, X., Essner, R., & Morton, D. L. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318158795b · Cited by 43
Immunosuppression in Melanoma Immunotherapy: Potential Opportunities for Intervention
Lizee, G. A., Radvanyi, L. G., Overwijk, W. W., & Hwu, P. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2537 · Cited by 39
Cited by
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
“All patients All doses 49 5 10 (3-22) 6 12 (5-25) 31 (17-45)”
InfluentialCTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition
Buchbinder, E. I., & Desai, A. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000239 · Cited by 2,360
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Metadata
- Authors
- Hino, R., Kabashima, K., Kato, Y., Yagi, H., Nakamura, M., Honjo, T., Okazaki, T., & Tokura, Y.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2010-02-08
- Volume
- 116
- Issue
- 7
- Pages
- 1757-1766
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2029086221
- Cited by
- 667
- References
- 36
- FWCI
- 11.11
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.